nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Paclitaxel—ovarian cancer	0.405	0.58	CbGbCtD
Rasagiline—BCL2—Docetaxel—ovarian cancer	0.293	0.42	CbGbCtD
Rasagiline—BCL2—Irinotecan—Topotecan—ovarian cancer	0.00434	1	CbGdCrCtD
Rasagiline—BCL2—epithelium—ovarian cancer	0.00311	0.0946	CbGeAlD
Rasagiline—BCL2—endometrium—ovarian cancer	0.00279	0.0848	CbGeAlD
Rasagiline—BCL2—gonad—ovarian cancer	0.00259	0.0786	CbGeAlD
Rasagiline—BCL2—uterus—ovarian cancer	0.00257	0.0781	CbGeAlD
Rasagiline—BCL2—female reproductive system—ovarian cancer	0.00231	0.0702	CbGeAlD
Rasagiline—BCL2—bone marrow—ovarian cancer	0.00218	0.0663	CbGeAlD
Rasagiline—BCL2—female gonad—ovarian cancer	0.00211	0.0639	CbGeAlD
Rasagiline—BCL2—testis—ovarian cancer	0.00187	0.0567	CbGeAlD
Rasagiline—MAOB—myometrium—ovarian cancer	0.00165	0.0502	CbGeAlD
Rasagiline—MAOB—embryo—ovarian cancer	0.00159	0.0482	CbGeAlD
Rasagiline—BCL2—lymph node—ovarian cancer	0.00135	0.0411	CbGeAlD
Rasagiline—MAOB—uterine cervix—ovarian cancer	0.00129	0.039	CbGeAlD
Rasagiline—MAOB—decidua—ovarian cancer	0.00122	0.0372	CbGeAlD
Rasagiline—MAOB—endometrium—ovarian cancer	0.00116	0.0353	CbGeAlD
Rasagiline—MAOB—uterus—ovarian cancer	0.00107	0.0325	CbGeAlD
Rasagiline—MAOB—female reproductive system—ovarian cancer	0.000963	0.0292	CbGeAlD
Rasagiline—MAOB—female gonad—ovarian cancer	0.000877	0.0266	CbGeAlD
Rasagiline—MAOB—vagina—ovarian cancer	0.000871	0.0264	CbGeAlD
Rasagiline—MAOB—testis—ovarian cancer	0.000777	0.0236	CbGeAlD
Rasagiline—MAOB—lymph node—ovarian cancer	0.000564	0.0171	CbGeAlD
Rasagiline—BCL2—ATF-2 transcription factor network—MAPK3—ovarian cancer	0.000195	0.00185	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000193	0.00183	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—AKT1—ovarian cancer	0.000191	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CAV1—ovarian cancer	0.000189	0.0018	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—ovarian cancer	0.000188	0.00179	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—ovarian cancer	0.000188	0.00179	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—AKT1—ovarian cancer	0.000187	0.00177	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000187	0.00177	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000187	0.00177	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000187	0.00177	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—MAPK1—ovarian cancer	0.000185	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—MAPK1—ovarian cancer	0.000185	0.00176	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CD—ovarian cancer	0.000185	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000183	0.00174	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MET—ovarian cancer	0.000183	0.00174	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—ovarian cancer	0.000183	0.00174	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PIK3CA—ovarian cancer	0.000181	0.00172	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—ovarian cancer	0.00018	0.00171	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—AKT1—ovarian cancer	0.000179	0.0017	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—ovarian cancer	0.000178	0.00169	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—ovarian cancer	0.000178	0.00169	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000177	0.00168	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—PIK3CA—ovarian cancer	0.000173	0.00164	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—ovarian cancer	0.000173	0.00164	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—APC—ovarian cancer	0.000172	0.00164	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—AKT1—ovarian cancer	0.000172	0.00164	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ESR1—ovarian cancer	0.000172	0.00163	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CASP3—ovarian cancer	0.000172	0.00163	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CASP3—ovarian cancer	0.00017	0.00162	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—ovarian cancer	0.00017	0.00161	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000169	0.0016	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000169	0.0016	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000169	0.0016	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—ovarian cancer	0.000167	0.00159	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MTOR—ovarian cancer	0.000166	0.00158	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—ovarian cancer	0.000166	0.00158	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—ovarian cancer	0.000166	0.00158	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—ovarian cancer	0.000164	0.00156	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—ovarian cancer	0.000164	0.00155	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000163	0.00155	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CB—ovarian cancer	0.000161	0.00153	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—ovarian cancer	0.00016	0.00152	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—ovarian cancer	0.00016	0.00152	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—APC—ovarian cancer	0.000159	0.00151	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000158	0.0015	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1B—ovarian cancer	0.000156	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—ovarian cancer	0.000155	0.00147	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NME2—ovarian cancer	0.000155	0.00147	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—ovarian cancer	0.000153	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MMP2—ovarian cancer	0.000153	0.00145	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—ovarian cancer	0.000152	0.00145	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1B—ovarian cancer	0.000151	0.00144	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	0.000149	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—ovarian cancer	0.000149	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CAV1—ovarian cancer	0.000148	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—ovarian cancer	0.000148	0.0014	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—ovarian cancer	0.000146	0.00139	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—ovarian cancer	0.000145	0.00137	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—ovarian cancer	0.000144	0.00137	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—MET—ovarian cancer	0.000143	0.00136	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—ovarian cancer	0.000143	0.00136	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—ovarian cancer	0.000143	0.00136	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—ovarian cancer	0.000143	0.00136	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—ovarian cancer	0.000142	0.00135	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000142	0.00135	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—ovarian cancer	0.000139	0.00133	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—MAPK3—ovarian cancer	0.000138	0.00131	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—MAPK3—ovarian cancer	0.000136	0.0013	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000136	0.0013	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CG—ovarian cancer	0.000135	0.00128	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—ovarian cancer	0.000135	0.00128	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000134	0.00128	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000134	0.00128	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—ovarian cancer	0.000132	0.00125	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—ovarian cancer	0.000131	0.00125	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—MAPK1—ovarian cancer	0.00013	0.00123	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—ovarian cancer	0.000124	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	0.000124	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CD—ovarian cancer	0.000119	0.00113	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EREG—ovarian cancer	0.000117	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IKBKG—ovarian cancer	0.000117	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—ovarian cancer	0.000117	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MAPK1—ovarian cancer	0.000117	0.00111	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—ovarian cancer	0.000116	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	0.000114	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—ovarian cancer	0.000114	0.00108	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MAPK1—ovarian cancer	0.000113	0.00108	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—ovarian cancer	0.000112	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—ovarian cancer	0.000112	0.00106	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	0.000111	0.00106	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00011	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	0.00011	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—ovarian cancer	0.00011	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—ovarian cancer	0.000108	0.00103	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	0.000107	0.00102	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—ovarian cancer	0.000107	0.00102	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000106	0.00101	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ERBB2—ovarian cancer	0.000105	0.000996	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000104	0.000992	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CB—ovarian cancer	0.000103	0.000983	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYTB—ovarian cancer	9.96e-05	0.000947	CbGpPWpGaD
Rasagiline—Orthostatic hypotension—Doxorubicin—ovarian cancer	9.91e-05	0.000619	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—ovarian cancer	9.9e-05	0.000941	CbGpPWpGaD
Rasagiline—Nervous system disorder—Paclitaxel—ovarian cancer	9.89e-05	0.000618	CcSEcCtD
Rasagiline—Angina pectoris—Epirubicin—ovarian cancer	9.87e-05	0.000617	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—ovarian cancer	9.84e-05	0.000935	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—ovarian cancer	9.81e-05	0.000932	CbGpPWpGaD
Rasagiline—Skin disorder—Paclitaxel—ovarian cancer	9.79e-05	0.000612	CcSEcCtD
Rasagiline—Hyperhidrosis—Paclitaxel—ovarian cancer	9.75e-05	0.000609	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	9.71e-05	0.000922	CbGpPWpGaD
Rasagiline—Anaemia—Docetaxel—ovarian cancer	9.68e-05	0.000605	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	9.67e-05	0.000919	CbGpPWpGaD
Rasagiline—Anorexia—Paclitaxel—ovarian cancer	9.61e-05	0.0006	CcSEcCtD
Rasagiline—Muscular weakness—Doxorubicin—ovarian cancer	9.57e-05	0.000598	CcSEcCtD
Rasagiline—Vomiting—Vinorelbine—ovarian cancer	9.53e-05	0.000595	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—ovarian cancer	9.52e-05	0.000905	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	9.48e-05	0.000901	CbGpPWpGaD
Rasagiline—Dysuria—Epirubicin—ovarian cancer	9.48e-05	0.000592	CcSEcCtD
Rasagiline—Rash—Vinorelbine—ovarian cancer	9.45e-05	0.000591	CcSEcCtD
Rasagiline—Dermatitis—Vinorelbine—ovarian cancer	9.44e-05	0.00059	CcSEcCtD
Rasagiline—Hypotension—Paclitaxel—ovarian cancer	9.42e-05	0.000589	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Epirubicin—ovarian cancer	9.42e-05	0.000589	CcSEcCtD
Rasagiline—Headache—Vinorelbine—ovarian cancer	9.39e-05	0.000587	CcSEcCtD
Rasagiline—Syncope—Docetaxel—ovarian cancer	9.39e-05	0.000587	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—ovarian cancer	9.38e-05	0.000891	CbGpPWpGaD
Rasagiline—Asthma—Doxorubicin—ovarian cancer	9.38e-05	0.000586	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—ovarian cancer	9.38e-05	0.000586	CcSEcCtD
Rasagiline—Influenza—Doxorubicin—ovarian cancer	9.38e-05	0.000586	CcSEcCtD
Rasagiline—Leukopenia—Docetaxel—ovarian cancer	9.37e-05	0.000586	CcSEcCtD
Rasagiline—Pollakiuria—Epirubicin—ovarian cancer	9.36e-05	0.000585	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—EGFR—ovarian cancer	9.28e-05	0.000882	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—ovarian cancer	9.26e-05	0.00088	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Epirubicin—ovarian cancer	9.25e-05	0.000578	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	9.23e-05	0.000877	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—ovarian cancer	9.21e-05	0.000875	CbGpPWpGaD
Rasagiline—Loss of consciousness—Docetaxel—ovarian cancer	9.2e-05	0.000575	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	9.19e-05	0.000574	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—ovarian cancer	9.17e-05	0.000872	CbGpPWpGaD
Rasagiline—Weight decreased—Epirubicin—ovarian cancer	9.17e-05	0.000573	CcSEcCtD
Rasagiline—Cough—Docetaxel—ovarian cancer	9.14e-05	0.000571	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	9.14e-05	0.000868	CbGpPWpGaD
Rasagiline—Angina pectoris—Doxorubicin—ovarian cancer	9.14e-05	0.000571	CcSEcCtD
Rasagiline—BCL2—Immune System—PVRL2—ovarian cancer	9.13e-05	0.000868	CbGpPWpGaD
Rasagiline—Insomnia—Paclitaxel—ovarian cancer	9.12e-05	0.00057	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—ovarian cancer	9.1e-05	0.000865	CbGpPWpGaD
Rasagiline—Convulsion—Docetaxel—ovarian cancer	9.07e-05	0.000567	CcSEcCtD
Rasagiline—Paraesthesia—Paclitaxel—ovarian cancer	9.05e-05	0.000566	CcSEcCtD
Rasagiline—Hypertension—Docetaxel—ovarian cancer	9.04e-05	0.000565	CcSEcCtD
Rasagiline—Infestation—Epirubicin—ovarian cancer	9.04e-05	0.000565	CcSEcCtD
Rasagiline—Infestation NOS—Epirubicin—ovarian cancer	9.04e-05	0.000565	CcSEcCtD
Rasagiline—Dyspnoea—Paclitaxel—ovarian cancer	8.99e-05	0.000562	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—ovarian cancer	8.98e-05	0.000853	CbGpPWpGaD
Rasagiline—Somnolence—Paclitaxel—ovarian cancer	8.96e-05	0.00056	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PTEN—ovarian cancer	8.94e-05	0.00085	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—ovarian cancer	8.93e-05	0.000849	CbGpPWpGaD
Rasagiline—Arthralgia—Docetaxel—ovarian cancer	8.91e-05	0.000557	CcSEcCtD
Rasagiline—Chest pain—Docetaxel—ovarian cancer	8.91e-05	0.000557	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	8.9e-05	0.000846	CbGpPWpGaD
Rasagiline—Nausea—Vinorelbine—ovarian cancer	8.9e-05	0.000556	CcSEcCtD
Rasagiline—Dyspepsia—Paclitaxel—ovarian cancer	8.87e-05	0.000555	CcSEcCtD
Rasagiline—Neuropathy peripheral—Epirubicin—ovarian cancer	8.86e-05	0.000554	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.85e-05	0.000553	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—ovarian cancer	8.81e-05	0.00055	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—ovarian cancer	8.81e-05	0.00055	CcSEcCtD
Rasagiline—Conjunctivitis—Epirubicin—ovarian cancer	8.78e-05	0.000549	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—ovarian cancer	8.77e-05	0.000548	CcSEcCtD
Rasagiline—Decreased appetite—Paclitaxel—ovarian cancer	8.76e-05	0.000548	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	8.74e-05	0.00083	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	8.74e-05	0.00083	CbGpPWpGaD
Rasagiline—Dry mouth—Docetaxel—ovarian cancer	8.72e-05	0.000545	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—ovarian cancer	8.72e-05	0.000545	CcSEcCtD
Rasagiline—MAOB—Metabolism—PPP1CC—ovarian cancer	8.71e-05	0.000828	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—BRIP1—ovarian cancer	8.71e-05	0.000828	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.7e-05	0.000544	CcSEcCtD
Rasagiline—Sweating—Epirubicin—ovarian cancer	8.66e-05	0.000541	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—ovarian cancer	8.66e-05	0.000541	CcSEcCtD
Rasagiline—Constipation—Paclitaxel—ovarian cancer	8.62e-05	0.000539	CcSEcCtD
Rasagiline—Haematuria—Epirubicin—ovarian cancer	8.62e-05	0.000538	CcSEcCtD
Rasagiline—Confusional state—Docetaxel—ovarian cancer	8.62e-05	0.000538	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—ovarian cancer	8.56e-05	0.000535	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—ovarian cancer	8.52e-05	0.000533	CcSEcCtD
Rasagiline—Infection—Docetaxel—ovarian cancer	8.49e-05	0.00053	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—ovarian cancer	8.48e-05	0.00053	CcSEcCtD
Rasagiline—Shock—Docetaxel—ovarian cancer	8.41e-05	0.000525	CcSEcCtD
Rasagiline—Nervous system disorder—Docetaxel—ovarian cancer	8.38e-05	0.000524	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—ovarian cancer	8.36e-05	0.000522	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—ovarian cancer	8.36e-05	0.000522	CcSEcCtD
Rasagiline—Feeling abnormal—Paclitaxel—ovarian cancer	8.31e-05	0.000519	CcSEcCtD
Rasagiline—Skin disorder—Docetaxel—ovarian cancer	8.3e-05	0.000519	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PPP2R1A—ovarian cancer	8.3e-05	0.000788	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	8.25e-05	0.000784	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.24e-05	0.000515	CcSEcCtD
Rasagiline—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.2e-05	0.000512	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—ovarian cancer	8.15e-05	0.000509	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—ovarian cancer	8.15e-05	0.000509	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—ovarian cancer	8.15e-05	0.000509	CcSEcCtD
Rasagiline—Anorexia—Docetaxel—ovarian cancer	8.15e-05	0.000509	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—ovarian cancer	8.13e-05	0.000508	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—ovarian cancer	8.13e-05	0.000508	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—ovarian cancer	8.11e-05	0.000507	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—ovarian cancer	8.08e-05	0.000768	CbGpPWpGaD
Rasagiline—Hypoaesthesia—Epirubicin—ovarian cancer	8.07e-05	0.000504	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.04e-05	0.000764	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—ovarian cancer	8.04e-05	0.000764	CbGpPWpGaD
Rasagiline—Sweating—Doxorubicin—ovarian cancer	8.02e-05	0.000501	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—ovarian cancer	8.01e-05	0.000501	CcSEcCtD
Rasagiline—Urticaria—Paclitaxel—ovarian cancer	8.01e-05	0.0005	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—ovarian cancer	7.99e-05	0.000499	CcSEcCtD
Rasagiline—Hypotension—Docetaxel—ovarian cancer	7.98e-05	0.000499	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—ovarian cancer	7.97e-05	0.000498	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—ovarian cancer	7.97e-05	0.000498	CcSEcCtD
Rasagiline—Abdominal pain—Paclitaxel—ovarian cancer	7.97e-05	0.000498	CcSEcCtD
Rasagiline—Body temperature increased—Paclitaxel—ovarian cancer	7.97e-05	0.000498	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—ovarian cancer	7.95e-05	0.000497	CcSEcCtD
Rasagiline—Epistaxis—Doxorubicin—ovarian cancer	7.89e-05	0.000493	CcSEcCtD
Rasagiline—BCL2—Immune System—PARK2—ovarian cancer	7.8e-05	0.000741	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—ovarian cancer	7.79e-05	0.00074	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.79e-05	0.000486	CcSEcCtD
Rasagiline—Insomnia—Docetaxel—ovarian cancer	7.73e-05	0.000483	CcSEcCtD
Rasagiline—Paraesthesia—Docetaxel—ovarian cancer	7.67e-05	0.000479	CcSEcCtD
Rasagiline—Dyspnoea—Docetaxel—ovarian cancer	7.62e-05	0.000476	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.61e-05	0.000723	CbGpPWpGaD
Rasagiline—Somnolence—Docetaxel—ovarian cancer	7.6e-05	0.000475	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—ovarian cancer	7.58e-05	0.000474	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—ovarian cancer	7.54e-05	0.000471	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—ovarian cancer	7.53e-05	0.00047	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—ovarian cancer	7.53e-05	0.00047	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—ovarian cancer	7.52e-05	0.00047	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—ovarian cancer	7.51e-05	0.000469	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—ovarian cancer	7.47e-05	0.000467	CcSEcCtD
Rasagiline—Decreased appetite—Docetaxel—ovarian cancer	7.43e-05	0.000464	CcSEcCtD
Rasagiline—Hypersensitivity—Paclitaxel—ovarian cancer	7.43e-05	0.000464	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—ovarian cancer	7.41e-05	0.000463	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	7.4e-05	0.000703	CbGpPWpGaD
Rasagiline—Oedema peripheral—Doxorubicin—ovarian cancer	7.39e-05	0.000462	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.38e-05	0.000461	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—ovarian cancer	7.38e-05	0.000461	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—ovarian cancer	7.36e-05	0.00046	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—ovarian cancer	7.36e-05	0.00046	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—ovarian cancer	7.33e-05	0.000697	CbGpPWpGaD
Rasagiline—Immune system disorder—Epirubicin—ovarian cancer	7.33e-05	0.000458	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—ovarian cancer	7.31e-05	0.000457	CcSEcCtD
Rasagiline—Constipation—Docetaxel—ovarian cancer	7.31e-05	0.000457	CcSEcCtD
Rasagiline—Chills—Epirubicin—ovarian cancer	7.28e-05	0.000455	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—MAPK1—ovarian cancer	7.27e-05	0.000691	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—ovarian cancer	7.27e-05	0.000691	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.24e-05	0.000688	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.24e-05	0.000688	CbGpPWpGaD
Rasagiline—Asthenia—Paclitaxel—ovarian cancer	7.23e-05	0.000452	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	7.2e-05	0.000684	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	7.2e-05	0.000684	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—ovarian cancer	7.18e-05	0.000683	CbGpPWpGaD
Rasagiline—Alopecia—Epirubicin—ovarian cancer	7.17e-05	0.000448	CcSEcCtD
Rasagiline—Pruritus—Paclitaxel—ovarian cancer	7.13e-05	0.000446	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—ovarian cancer	7.11e-05	0.000444	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—ovarian cancer	7.06e-05	0.000441	CcSEcCtD
Rasagiline—Feeling abnormal—Docetaxel—ovarian cancer	7.04e-05	0.00044	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	7.04e-05	0.000669	CbGpPWpGaD
Rasagiline—Eye disorder—Doxorubicin—ovarian cancer	7.02e-05	0.000438	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—ovarian cancer	6.99e-05	0.000437	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—ovarian cancer	6.97e-05	0.000435	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—ovarian cancer	6.96e-05	0.000435	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—ovarian cancer	6.92e-05	0.000432	CcSEcCtD
Rasagiline—Diarrhoea—Paclitaxel—ovarian cancer	6.9e-05	0.000431	CcSEcCtD
Rasagiline—BCL2—Immune System—IKBKG—ovarian cancer	6.84e-05	0.00065	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EREG—ovarian cancer	6.84e-05	0.00065	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	6.84e-05	0.00065	CbGpPWpGaD
Rasagiline—Back pain—Epirubicin—ovarian cancer	6.83e-05	0.000427	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—ovarian cancer	6.81e-05	0.000426	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—ovarian cancer	6.79e-05	0.000424	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—ovarian cancer	6.78e-05	0.000424	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—ovarian cancer	6.77e-05	0.000423	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—ovarian cancer	6.76e-05	0.000422	CcSEcCtD
Rasagiline—Abdominal pain—Docetaxel—ovarian cancer	6.76e-05	0.000422	CcSEcCtD
Rasagiline—Chills—Doxorubicin—ovarian cancer	6.74e-05	0.000421	CcSEcCtD
Rasagiline—BCL2—Immune System—SKP2—ovarian cancer	6.68e-05	0.000635	CbGpPWpGaD
Rasagiline—Dizziness—Paclitaxel—ovarian cancer	6.67e-05	0.000417	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—ovarian cancer	6.63e-05	0.000414	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—ovarian cancer	6.58e-05	0.000411	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—ovarian cancer	6.55e-05	0.000409	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—ovarian cancer	6.53e-05	0.000408	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—ovarian cancer	6.53e-05	0.000408	CcSEcCtD
Rasagiline—Agitation—Epirubicin—ovarian cancer	6.49e-05	0.000406	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—ovarian cancer	6.44e-05	0.000402	CcSEcCtD
Rasagiline—Vomiting—Paclitaxel—ovarian cancer	6.41e-05	0.000401	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—ovarian cancer	6.4e-05	0.0004	CcSEcCtD
Rasagiline—Malaise—Epirubicin—ovarian cancer	6.37e-05	0.000398	CcSEcCtD
Rasagiline—Rash—Paclitaxel—ovarian cancer	6.36e-05	0.000397	CcSEcCtD
Rasagiline—Dermatitis—Paclitaxel—ovarian cancer	6.35e-05	0.000397	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—ovarian cancer	6.35e-05	0.000396	CcSEcCtD
Rasagiline—Syncope—Epirubicin—ovarian cancer	6.33e-05	0.000396	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—ovarian cancer	6.32e-05	0.000395	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—ovarian cancer	6.32e-05	0.000395	CcSEcCtD
Rasagiline—Headache—Paclitaxel—ovarian cancer	6.32e-05	0.000395	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—ovarian cancer	6.31e-05	0.000599	CbGpPWpGaD
Rasagiline—Hypersensitivity—Docetaxel—ovarian cancer	6.3e-05	0.000393	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—ovarian cancer	6.28e-05	0.000393	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.28e-05	0.000597	CbGpPWpGaD
Rasagiline—Loss of consciousness—Epirubicin—ovarian cancer	6.21e-05	0.000388	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	6.19e-05	0.000589	CbGpPWpGaD
Rasagiline—Cough—Epirubicin—ovarian cancer	6.16e-05	0.000385	CcSEcCtD
Rasagiline—Asthenia—Docetaxel—ovarian cancer	6.13e-05	0.000383	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—ovarian cancer	6.12e-05	0.000382	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—ovarian cancer	6.1e-05	0.000381	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.08e-05	0.000578	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—ovarian cancer	6.07e-05	0.000576	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Doxorubicin—ovarian cancer	6.06e-05	0.000379	CcSEcCtD
Rasagiline—Pruritus—Docetaxel—ovarian cancer	6.05e-05	0.000378	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—ovarian cancer	6.04e-05	0.000377	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—TLR4—ovarian cancer	6.03e-05	0.000573	CbGpPWpGaD
Rasagiline—Chest pain—Epirubicin—ovarian cancer	6.01e-05	0.000376	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—ovarian cancer	6.01e-05	0.000376	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—ovarian cancer	6.01e-05	0.000375	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—ovarian cancer	5.99e-05	0.000374	CcSEcCtD
Rasagiline—Nausea—Paclitaxel—ovarian cancer	5.99e-05	0.000374	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	5.98e-05	0.000569	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.97e-05	0.000373	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—ovarian cancer	5.94e-05	0.000371	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	5.91e-05	0.000562	CbGpPWpGaD
Rasagiline—Malaise—Doxorubicin—ovarian cancer	5.89e-05	0.000368	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—ovarian cancer	5.88e-05	0.000367	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—ovarian cancer	5.87e-05	0.000367	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	5.87e-05	0.000558	CbGpPWpGaD
Rasagiline—Syncope—Doxorubicin—ovarian cancer	5.86e-05	0.000366	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—ovarian cancer	5.85e-05	0.000365	CcSEcCtD
Rasagiline—Diarrhoea—Docetaxel—ovarian cancer	5.85e-05	0.000365	CcSEcCtD
Rasagiline—MAOB—Metabolism—YAP1—ovarian cancer	5.84e-05	0.000555	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—HRAS—ovarian cancer	5.84e-05	0.000555	CbGpPWpGaD
Rasagiline—Confusional state—Epirubicin—ovarian cancer	5.81e-05	0.000363	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	5.79e-05	0.00055	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6ST—ovarian cancer	5.78e-05	0.000549	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—ovarian cancer	5.74e-05	0.000359	CcSEcCtD
Rasagiline—Infection—Epirubicin—ovarian cancer	5.73e-05	0.000358	CcSEcCtD
Rasagiline—Cough—Doxorubicin—ovarian cancer	5.7e-05	0.000356	CcSEcCtD
Rasagiline—Shock—Epirubicin—ovarian cancer	5.67e-05	0.000354	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—ovarian cancer	5.66e-05	0.000354	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—ovarian cancer	5.65e-05	0.000353	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—ovarian cancer	5.65e-05	0.000353	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—ovarian cancer	5.64e-05	0.000353	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—ovarian cancer	5.6e-05	0.00035	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—ovarian cancer	5.57e-05	0.000348	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—ovarian cancer	5.56e-05	0.000348	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—ovarian cancer	5.56e-05	0.000348	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—ovarian cancer	5.54e-05	0.000346	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.52e-05	0.000345	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	5.51e-05	0.000523	CbGpPWpGaD
Rasagiline—Discomfort—Doxorubicin—ovarian cancer	5.5e-05	0.000343	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—ovarian cancer	5.49e-05	0.000343	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—ovarian cancer	5.44e-05	0.00034	CcSEcCtD
Rasagiline—Vomiting—Docetaxel—ovarian cancer	5.43e-05	0.000339	CcSEcCtD
Rasagiline—Rash—Docetaxel—ovarian cancer	5.39e-05	0.000337	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	5.39e-05	0.000512	CbGpPWpGaD
Rasagiline—Hypotension—Epirubicin—ovarian cancer	5.39e-05	0.000337	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	5.39e-05	0.000512	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	5.39e-05	0.000512	CbGpPWpGaD
Rasagiline—Dermatitis—Docetaxel—ovarian cancer	5.38e-05	0.000336	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—ovarian cancer	5.38e-05	0.000336	CcSEcCtD
Rasagiline—Headache—Docetaxel—ovarian cancer	5.35e-05	0.000335	CcSEcCtD
Rasagiline—Infection—Doxorubicin—ovarian cancer	5.3e-05	0.000331	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.25e-05	0.000328	CcSEcCtD
Rasagiline—Shock—Doxorubicin—ovarian cancer	5.25e-05	0.000328	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—ovarian cancer	5.23e-05	0.000327	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—ovarian cancer	5.21e-05	0.000326	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—ovarian cancer	5.18e-05	0.000324	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—ovarian cancer	5.18e-05	0.000323	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—ovarian cancer	5.16e-05	0.000322	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—ovarian cancer	5.15e-05	0.00049	CbGpPWpGaD
Rasagiline—Dyspnoea—Epirubicin—ovarian cancer	5.14e-05	0.000321	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.13e-05	0.000488	CbGpPWpGaD
Rasagiline—Somnolence—Epirubicin—ovarian cancer	5.12e-05	0.00032	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	5.09e-05	0.000483	CbGpPWpGaD
Rasagiline—Anorexia—Doxorubicin—ovarian cancer	5.08e-05	0.000318	CcSEcCtD
Rasagiline—Nausea—Docetaxel—ovarian cancer	5.08e-05	0.000317	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—ovarian cancer	5.07e-05	0.000317	CcSEcCtD
Rasagiline—Decreased appetite—Epirubicin—ovarian cancer	5.01e-05	0.000313	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—ovarian cancer	4.98e-05	0.000311	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.98e-05	0.000311	CcSEcCtD
Rasagiline—Constipation—Epirubicin—ovarian cancer	4.93e-05	0.000308	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CD—ovarian cancer	4.88e-05	0.000464	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.86e-05	0.000304	CcSEcCtD
Rasagiline—BCL2—Immune System—PPP2R1A—ovarian cancer	4.83e-05	0.000459	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—ovarian cancer	4.82e-05	0.000301	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—ovarian cancer	4.79e-05	0.000299	CcSEcCtD
Rasagiline—MAOB—Metabolism—FASN—ovarian cancer	4.76e-05	0.000452	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—ovarian cancer	4.75e-05	0.000297	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—ovarian cancer	4.75e-05	0.000297	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—ovarian cancer	4.74e-05	0.000296	CcSEcCtD
Rasagiline—Gastrointestinal pain—Epirubicin—ovarian cancer	4.71e-05	0.000295	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—ovarian cancer	4.69e-05	0.000293	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC5A5—ovarian cancer	4.68e-05	0.000445	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—ovarian cancer	4.64e-05	0.00029	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.6e-05	0.000288	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—ovarian cancer	4.58e-05	0.000286	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—ovarian cancer	4.56e-05	0.000285	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—ovarian cancer	4.56e-05	0.000285	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—ovarian cancer	4.56e-05	0.000285	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.53e-05	0.00043	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC2A1—ovarian cancer	4.52e-05	0.00043	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—ovarian cancer	4.39e-05	0.000275	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.36e-05	0.000272	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP1B1—ovarian cancer	4.34e-05	0.000412	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.32e-05	0.000411	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—ovarian cancer	4.31e-05	0.00041	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—ovarian cancer	4.31e-05	0.000409	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CB—ovarian cancer	4.26e-05	0.000404	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MTOR—ovarian cancer	4.26e-05	0.000404	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—ovarian cancer	4.25e-05	0.000265	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—ovarian cancer	4.24e-05	0.000265	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—ovarian cancer	4.22e-05	0.000263	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—ovarian cancer	4.22e-05	0.000263	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—ovarian cancer	4.14e-05	0.000258	CcSEcCtD
Rasagiline—Pruritus—Epirubicin—ovarian cancer	4.08e-05	0.000255	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1B—ovarian cancer	3.99e-05	0.000379	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—ovarian cancer	3.94e-05	0.000246	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—ovarian cancer	3.93e-05	0.000246	CcSEcCtD
Rasagiline—MAOB—Metabolism—PPP2R1A—ovarian cancer	3.85e-05	0.000366	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—ovarian cancer	3.83e-05	0.000239	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—ovarian cancer	3.81e-05	0.000238	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—ovarian cancer	3.77e-05	0.000236	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CTNNB1—ovarian cancer	3.77e-05	0.000359	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—ovarian cancer	3.68e-05	0.000349	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—ovarian cancer	3.66e-05	0.000229	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—ovarian cancer	3.65e-05	0.000228	CcSEcCtD
Rasagiline—Rash—Epirubicin—ovarian cancer	3.63e-05	0.000227	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—ovarian cancer	3.63e-05	0.000227	CcSEcCtD
Rasagiline—Headache—Epirubicin—ovarian cancer	3.61e-05	0.000226	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—NME2—ovarian cancer	3.58e-05	0.00034	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCB1—ovarian cancer	3.57e-05	0.000339	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—ovarian cancer	3.53e-05	0.00022	CcSEcCtD
Rasagiline—BCL2—Immune System—TLR4—ovarian cancer	3.51e-05	0.000334	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMS—ovarian cancer	3.51e-05	0.000333	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—ovarian cancer	3.42e-05	0.000214	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—ovarian cancer	3.39e-05	0.000212	CcSEcCtD
Rasagiline—BCL2—Immune System—IL6ST—ovarian cancer	3.37e-05	0.00032	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—ovarian cancer	3.36e-05	0.00021	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—ovarian cancer	3.36e-05	0.00021	CcSEcCtD
Rasagiline—Headache—Doxorubicin—ovarian cancer	3.34e-05	0.000209	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRAS—ovarian cancer	3.28e-05	0.000312	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—ovarian cancer	3.17e-05	0.000198	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK3—ovarian cancer	3.14e-05	0.000299	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.04e-05	0.000288	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK1—ovarian cancer	2.99e-05	0.000284	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—ovarian cancer	2.99e-05	0.000284	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—ovarian cancer	2.98e-05	0.000283	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—ovarian cancer	2.84e-05	0.00027	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAV1—ovarian cancer	2.83e-05	0.000269	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—ovarian cancer	2.82e-05	0.000268	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—ovarian cancer	2.59e-05	0.000247	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—ovarian cancer	2.57e-05	0.000245	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—ovarian cancer	2.51e-05	0.000239	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MTOR—ovarian cancer	2.48e-05	0.000236	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—ovarian cancer	2.48e-05	0.000236	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.47e-05	0.000235	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—ovarian cancer	2.4e-05	0.000228	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—ovarian cancer	2.33e-05	0.000221	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYTB—ovarian cancer	2.31e-05	0.000219	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—ovarian cancer	2.3e-05	0.000218	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—ovarian cancer	2.28e-05	0.000216	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—ovarian cancer	2.26e-05	0.000215	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.25e-05	0.000214	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—ovarian cancer	2.2e-05	0.000209	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—ovarian cancer	2.14e-05	0.000204	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—ovarian cancer	2.12e-05	0.000201	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.02e-05	0.000192	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.02e-05	0.000192	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—ovarian cancer	1.97e-05	0.000187	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—ovarian cancer	1.92e-05	0.000182	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—ovarian cancer	1.91e-05	0.000182	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK3—ovarian cancer	1.83e-05	0.000174	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK1—ovarian cancer	1.74e-05	0.000165	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—ovarian cancer	1.74e-05	0.000165	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—ovarian cancer	1.7e-05	0.000162	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—ovarian cancer	1.64e-05	0.000156	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—ovarian cancer	1.51e-05	0.000144	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.47e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—ovarian cancer	1.4e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—YAP1—ovarian cancer	1.35e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.34e-05	0.000127	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—ovarian cancer	1.23e-05	0.000117	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—ovarian cancer	1.2e-05	0.000114	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.18e-05	0.000112	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FASN—ovarian cancer	1.1e-05	0.000105	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.08e-05	0.000103	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.05e-05	9.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.03e-05	9.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1e-05	9.54e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—ovarian cancer	9.82e-06	9.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	8.9e-06	8.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.86e-06	8.42e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—ovarian cancer	8.27e-06	7.85e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—ovarian cancer	8.12e-06	7.71e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAV1—ovarian cancer	6.54e-06	6.22e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.25e-06	5.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.96e-06	5.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—ovarian cancer	5.24e-06	4.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.57e-06	4.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—ovarian cancer	3.94e-06	3.75e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.78e-06	2.64e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—ovarian cancer	2.27e-06	2.16e-05	CbGpPWpGaD
